Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...

Pfizer and Zhejiang Hisun to Invest $545 Million in Generic Drug JV

publication date: Feb 20, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Pfizer and Zhejiang Hisun Pharma will put $545 million of assets into their branded generics JV. The investment will consist of off-patent drugs, manufacturing sites and cash. Hisun will contribute $295 million of these assets for a 51% stake in the JV, while Pfizer’s portion will be $250 million for the remaining 49%. The two companies signed a MOU to set up the JV in June 2011, and they have now made progress by approving a framework agreement and releasing the financial commitments of each party. More details....

Stock Symbols: (NYSE: PFE) (SHA: 600267)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Investor Forum
2013-Shanhai
September 4-5,2013
Shanghai, China

ChinaBio® Leadership Retraet
2013-Suzhou
October 24-25, 2013
Suzhou, China

ChinaBio® Investor Forum
2013-Wuhan
December 4-5,2013
Wuhan, China
>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

China Forum 2013
November 3, 2013
Vienna, Austria

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners